Search Result

15 search results for Histiocytic Neoplasms

NCCN Guidelines Histiocytic Neoplasms

NCCN Guidelines Histiocytic Neoplasms, NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms

https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

Erdheim-Chester Disease

NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms

https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

Langerhans Cell Histiocytosis

NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms

https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

Rosai-Dorfman Disease

NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms

https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf

Permission to Cite or Use NCCN Content

Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Lung Cancer Screening, Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Malignant Pleural, Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Growth Factors Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Cell Transplantation Hematopoietic Growth Factors Hepatocellular Carcinoma Histiocytic Neoplasms

https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-content

Recently Updated Guidelines

Tumors Version 1.2024 Histiocytic Neoplasms Version 1.2024 Hodgkin Lymphoma, NCCN Guidelines with Evidence Blocks - Histiocytic Neoplasms Version 1.2024 NCCN, Cancer Version 1.2024 Thyroid Carcinoma Version 2.2024 Uterine Neoplasms Version, - Uterine Neoplasms Version 2.2024 Guidelines for Detection, Prevention, & Risk Reduction

https://www.nccn.org/guidelines/recently-published-guidelines

Guidelines Panels

Cancers Panel Histiocytic Neoplasms, Myeloproliferative Neoplasms Panel

https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panels

Treatment by Cancer Type

Version: 2.2023 Histiocytic Neoplasms, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version: 1.2024 Myeloproliferative Neoplasms, Neoplasms Version: 2.2024 Vaginal Cancer

https://www.nccn.org/guidelines/category_1

Submission Request Form

Hepatobiliary Cancers - 1.2023 Hepatocellular Carcinoma - 1.2024 Histiocytic Neoplasms - 1.2024 Hodgkin, - 1.2024 Multiple Myeloma - 4.2024 Myelodysplastic Syndromes - 1.2024 Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions - 1.2024 Myeloproliferative Neoplasms - 1.2024, Neoplasms - 2.2024 Vaginal Cancer - 1.2025 Vulvar Cancer - 4.2024 Waldenström Macroglobulinemia

https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-form

Resume Screening

Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Mesothelioma: Pleural Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma, and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal Cancer Vulvar Cancer, Fungoides/Sézary Syndrome Myelodysplastic Syndromes Myeloproliferative Neoplasms Nasopharyngeal

https://www.nccn.org/covid-19/resume-screening

Transparency Process

Version: 2.2024 ( Uterine Neoplasms ) Date: 2024-02-29 Meeting, Disclosures/Attendance Version: 1.2024 ( Uterine Neoplasms ) Date: 2023-06-30 Meeting, Neoplasms ) Date: 2023-04-07 Meeting Evidence Panel Disclosures/Attendance Version: 2.2023 ( Uterine Neoplasms ) Date: 2023-03-21 Meeting Evidence Panel Disclosures, Panel Disclosures/Attendance Version: 1.2023 ( Uterine Neoplasms ) Date: 2022-11-14

https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendations

Guidelines With Evidence Blocks

Version 3.2024 Hepatocellular Carcinoma Version 2.2023 Histiocytic Neoplasms Version, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 1.2024 Myeloproliferative Neoplasms Version 1.2024 Neuroendocrine and Adrenal Tumors, Version 1.2024 Thyroid Carcinoma Version 2.2024 Uterine Neoplasms Version 2.2024

https://www.nccn.org/guidelines/guidelines-with-evidence-blocks

Chemotherapy Order Templates Reviewer Acknowledgement

, BCOP Roswell Park Comprehensive Cancer Center Histiocytic Neoplasms Jeri Angelo, PharmD, BCOP UC Davis, Moffitt Cancer Center Myeloproliferative Neoplasms, University of Michigan Rogel Cancer Center Uterine Neoplasms

https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagement

Submission Request History

for Uterine Neoplasms Submitted by Bristol-Myers Squibb Company on 12/04/2019 Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020 Pembrolizumab Submitted, dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020 Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GlaxoSmithKline on 05/15/2020 Pembrolizumab, Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020 Pembrolizumab for Vulvar Cancer

https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-history

Annual Report 2023

neoplasms. These clinical resources were also translated into Chinese by leading experts in the region

https://www.nccn.org/docs/default-source/about/annual-report-2023.pdf?sfvrsn=8411082_31